Quarterly report [Sections 13 or 15(d)]

Segment Information

v3.25.2
Segment Information
 6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Segment Information

Note 8 – Segment Information

 

The Company operates and manages its business as one reportable and operating as a clinical stage biopharmaceutical company focused on the development and commercialization of novel immune-oncology products based on our proprietary Tri-specific Killer Engager (TriKE®), and Tetra-specific Killer Engager (Dual Targeting TriKE®) platforms. The measure of segment assets is reported on the balance sheet as total assets.

 

The Company’s CODM reviews financial information presented and decides how to allocate resources based on net income (loss). Net income (loss) is used for evaluating financial performance.

 

Significant segment expenses include research and development, salaries, insurance, and stock-based compensation. Operating expenses include all remaining costs necessary to operate our business, which primarily include external professional services and other administrative expenses. The following table presents the significant segment expenses and other segment items regularly reviewed by our CODM:

 

    2025     2024     2025     2024  
    Three Months Ended June 30,     Six Months Ended June 30,  
    2025     2024     2025     2024  
Research and development   $ 363,000     $ 1,805,000     $ 1,462,000     $ 2,561,000  
Salaries     351,000       287,000       632,000       765,000  
Insurance     61,000       76,000       121,000       152,000  
Stock-based compensation     4,000       120,000       7,000       222,000  
Operating expenses     734,000       1,619,000       1,223,000       3,297,000  
Other income     (80,000 )     (197,000 )     (1,236,000 )     (1,021,000 )
Net loss   $ 1,433,000     $ 3,710,000     $ 2,209,000     $ 5,976,000